PI3K/AKT/mTOR信号通路在Burkitt淋巴瘤中的研究进展

Burkitt淋巴瘤是一种高度侵袭性的非霍奇金淋巴瘤,是人类生长最快的肿瘤。根据流行病学及miRNA不同,分为地方型、散发型与免疫缺陷相关型。该病主要发生在儿童及青少年,少数发生于成年人。经短期、强效化疗后疗效显著,但成年、晚期、耐药的患者预后较差。PI3K/AKT/mTOR信号通路在细胞的生长、分化、代谢、生存以及增殖等方面发挥重要作用,研究发现,该信号通路在Burkitt淋巴瘤中呈激活状态,且针对该通路的抑制剂对Burkitt淋巴瘤细胞有抑制作用。通过对该信号通路与PTEN、c-Myc、自噬在Burkitt淋巴瘤中作用及相互关系的研究,了解其发病机制,设计该通路抑制剂与其他相关通路抑制剂或与单克隆抗体的联合用药,为晚期、耐药的患者寻找精准、高效、低毒的靶向治疗方案。

Research Progress on PI3K/AKT/mTOR Signaling Pathway in Burkitt Lymphoma

Burkitt lymphoma is a highly aggressive subtype of non-Hodgkin lymphoma. And it is one of the fastest growing human tumors. The lymphoma can be divided into three subclasses: endemic type, sporadic type and immunodeficiency-associated type, according to epidemiology and different miRNA profiles. The disease is often found in children and teenagers, rarely in the adults. Outcome with short and intensive chemotherapy is excellent. But the prognosis is poor in adults who are in later period and resistant to therapy. PI3K/AKT/mTOR signaling pathway plays an important role in kinds of cellular functions, including growing, differentiation, metabolism, survival and proliferation. Studies have shown that the PI3K/AKT/mTOR signaling pathway is activated in Burkitt lymphoma, and the inhibitors of this pathway inhibit Burkitt lymphoma cells. We understand the pathogenesis of Burkitt lymphoma by exploring the effects and interaction of PTEN, c-Myc, autophagy and PI3K/AKT/mTOR signaling pathway. And we will manage the combination of PI3K/AKT/mTOR signaling pathway inhibitors with monoclonal antibodies or other pathway inhibitors to find accurate, effective and low-toxic targeted therapy for the adults with drug resistance or in later period.